METABOLIK JIGAR YOG‘ KASALLIGI BILAN OG‘RIGAN BEMORLARDA PARODONTITNING ETIOLOGIYASI VA PATOGENEZI TO‘G‘RISIDAGI ZAMONAVIY TASAVVURLAR
##article.subject##:
parodontit, MASLD, tizimli yallig‘lanish, metabolik yo‘llar, insulinrezistentlik, prognoz, profilaktika##article.abstract##
Maqolada parodontit va metabolik bog‘liq jigar yog‘ kasalligi (MAJBP, MASLD) o‘rtasidagi o‘zaro bog‘liqlik haqidagi zamonaviy qarashlar ko‘rib chiqilgan. Tizimli yallig‘lanish, oksidativ stress, mikrobiota disbiozi va insulinga rezistentlikni o‘z ichiga olgan umumiy patogenetik mexanizmlar mavjudligini tasdiqlovchi adabiyot ma’lumotlari tahlil qilingan. Parodontal patogenlar tizimli qon oqimiga kirib, jigarning Toll-like retseptorlarini faollashtirishga va yallig‘lanish reaksiyasini kuchaytirishga yordam beradi, bu esa steatoz va jigar fibrozining rivojlanishida muhim rol o‘ynaydi. O‘z navbatida, MASLDda metabolik jarayonlarning buzilishi antioksidant himoyaning pasayishi va qon tomir reaktivligining o‘zgarishi tufayli parodontitning kechishini og‘irlashtiradi. Ikkala kasallikni bog‘laydigan asosiy metabolik yo‘llar, jumladan TLR4/NF-κB faollashuvi, insulin signalizatsiyasining buzilishi (PI3K/Akt) va PPAR-γ disregulyatsiyasi aniqlangan. Prognozning potensial mezonlari - CRP, IL-6, TNF-α darajasi, HOMA-IR va jigar fermentlari faolligi ko‘rsatkichlari, shuningdek parodontning klinik indekslari taqdim etilgan. Yallig‘lanish va metabolik buzilishlarni korreksiyalashga qaratilgan multidissiplinar yondashuv va erta profilaktika zarurligi qayd etilgan.
Библиографические ссылки
Kinane D.F., Stathopoulou P.G., Papapanou P.N. Periodontal diseases. Nat Rev Dis Primers, 2017; 3:17038.
Eslam M., Newsome P.N., et al. A new definition for metabolic dysfunction-associated steatotic liver disease. J Hepatol, 2023;78(2):379–392.
Hotamisligil G.S. Inflammation and metabolic disorders. Nature, 2022;604(7907):517–526.
Sasaki N., et al. Porphyromonas gingivalis infection and liver steatosis. J Gastroenterol Hepatol, 2018;33(4):944–951.
Kobayashi R., et al. Relationship between periodontal disease and non-alcoholic fatty liver disease. J Clin Periodontol, 2020;47(6):651–661.
Akazawa H., et al. Effects of periodontal therapy on systemic inflammation and liver enzymes. Clin Oral Investig, 2021;25(12):6517–6525.
Yoneda M., et al. Periodontitis and metabolic syndrome: systemic inflammatory network. J Hepatol, 2022;76(3):734–743.
Wang X., et al. Interaction between insulin resistance and periodontitis. Front Endocrinol, 2021;12:665240.
Bartold P.M., Van Dyke T.E. An appraisal of the role of specific bacteria in the initial pathogenesis of periodontitis. J Clin Periodontol. 2019;46:6–11.
Targher G., Byrne C.D., Tilg H. Non-alcoholic fatty liver disease: a multisystem disease. J Hepatol. 2020;72:371–384.
Preshaw P.M., Alba A.L., Herrera D. Periodontitis and systemic health: current status. J Clin Periodontol. 2012;39:14–19.
Amar S., et al. Periodontal disease, systemic inflammation, and metabolic syndrome. J Dent Res. 2007;86:400–410.
Shibata Y., et al. Inflammatory markers in periodontitis and NAFLD. Clin Oral Investig. 2018;22:283–292.
Socransky S.S., Haffajee A.D. Microbial complexes in subgingival plaque. J Clin Periodontol. 2005;25:134–144.
Akinkugbe A.O., et al. Insulin resistance and periodontal disease in NAFLD patients. Diabetes Care. 2016;39:1392–1398.
Al-Khabbaz A.K., et al. Lipid metabolism and periodontal inflammation. J Periodontol. 2013;84:1435–1443.
Laine M.L., et al. Genetic susceptibility to periodontitis. Periodontol 2000. 2012;58:37–49.
Kinane D.F., et al. Host–response mechanisms in periodontitis. Periodontol 2000. 2017;75:11–20.
Preshaw P.M., et al. Oxidative stress in periodontal disease. Periodontol 2000. 2011;55:107–125.
Sanz M., et al. Periodontitis and systemic diseases: association with liver disease. J Clin Periodontol. 2019;46:119–136.
Yoneda M., et al. Association between periodontitis and liver fibrosis in NAFLD patients. Hepatol Res. 2017;47:1276–1283.
Tonetti M.S., et al. Periodontitis: clinical practice guideline. J Clin Periodontol. 2020;47:4–60.
Preshaw P.M., et al. Periodontal therapy in patients with systemic diseases. Periodontol 2000. 2019;80:190–206.
Lee et al. (2024). Metabolic Dysfunction-Associated Steatotic Liver Disease and the Risk of Chronic Periodontitis: A Nationwide Cohort Study. BMC Oral Health. https://pubmed.ncbi.nlm.nih.gov/39796559/
Li et al. (2025). Association between periodontitis and mortality in participants with metabolic dysfunction-associated steatotic liver disease: results from NHANES. BMC Oral Health. https://bmcoralhealth.biomedcentral.com/articles/10.1186/s12903-025-05959-7
Sato et al. (2023). The Presence of Periodontitis Exacerbates Non-Alcoholic Fatty Liver Disease via Sphingolipid Metabolism-Associated Insulin Resistance and Hepatic Inflammation in Mice with Metabolic Syndrome. Int. J. Mol. Sci. https://www.mdpi.com/1422-0067/24/9/8322
